FDA accepted Bayer's application for Nubeqa, an oral androgen receptor inhibitor, for metastatic hormone-sensitive prostate cancer treatment. The Phase III ARANOTE trial showed positive results. Bayer aims to expand Nubeqa's indication to benefit more patients.